Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842500 | 0.94 | PTPN11 (0.50) | NR3C2SMN1; SMN2PTPN11ESR1CYP3A4 | |
| SCHEMBL16373430 | 0.89 | PTPN11 (0.46) | NR3C2SMN1; SMN2PTPN11CA1CA2 | |
| SCHEMBL15165487 | 0.88 | CA1 (0.47) | NR3C2SMN1; SMN2PTPN11CA1CA2 | |
| SCHEMBL9567821 | 0.86 | ESR1 (0.53) | PTPN11ALDH1A1ESR1CYP3A4ESR2 | |
| SCHEMBL18343094 | 0.86 | NR3C2 (0.49) | NR3C2SMN1; SMN2ALDH1A1ESR1CYP3A4 | |
| SCHEMBL12960114 | 0.85 | CA2 (0.47) | ALDH1A1ESR2CA1CA2CA9 | |
| SCHEMBL3842511 | 0.85 | CA2 (0.47) | ALDH1A1ESR2CA1CA2CA9 | |
| SCHEMBL16394707 | 0.85 | NR3C2 (0.51) | NR3C2SMN1; SMN2ALDH1A1ESR1CYP3A4 | |
| SCHEMBL17725466 | 0.84 | SMN1; SMN2 (0.43) | NR3C2SMN1; SMN2PTPN11ALDH1A1ESR1 | |
| SCHEMBL2689080 | 0.84 | NR3C2 (0.54) | NR3C2SMN1; SMN2ALDH1A1ESR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12201015-B2 | Iridium complex compound, composition containing the compound and solvent, organic electroluminescent element containing the compound, display device, and illumination device | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-01-14 | — | — | US | disclosed |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| US-20230131195-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | DUPONT SPECIALTY MATERIALS KOREA LTD. (KR) | 2023-04-27 | — | — | US | disclosed |
| EP-3971196-A1 | IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING SAID COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING SAID COMPOUND, DISPLAY DEVICE AND LIGHTING DEVICE | Mitsubishi Chemical Corporation (JP) | 2022-03-23 | — | — | EP | disclosed |
| US-11279713-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-22 | — | — | US | disclosed |
| US-20220069238-A1 | IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING THE COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THE COMPOUND, DISPLAY DEVICE, AND ILLUMINATION DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-03 | — | — | US | disclosed |
| CN-113853381-A | Iridium complex compound, composition containing iridium complex compound and solvent, organic electroluminescent element containing iridium complex compound, display device, and lighting device | 三菱化学株式会社 | 2021-12-28 | — | — | CN | disclosed |
| WO-2020230811-A1 | IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING SAID COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING SAID COMPOUND, DISPLAY DEVICE AND LIGHTING DEVICE | 三菱ケミカル株式会社 | 2020-11-19 | — | — | WO | disclosed |
| WO-2020230811-A1 | IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING SAID COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING SAID COMPOUND, DISPLAY DEVICE AND LIGHTING DEVICE | 三菱ケミカル株式会社 | 2020-11-19 | — | — | WO | disclosed |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-08 | — | — | US | disclosed |
| EP-2609071-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | Novartis AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| EP-2603513-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120077799-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| WO-2012025502-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012020848-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | WO | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2283020-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009143051-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201015-B2 | Iridium complex compound, composition containing the compound and solvent, organic electroluminescent element containing the compound, display device, and illumination device | INF2, EMC2, INTS9 | NR3C2 619/4885SMN1; SMN2 2768/4885PTPN11 2215/4885 |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | NR3C2 167/4885SMN1; SMN2 2000/4885PTPN11 749/4885 |
| US-20230131195-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | OR10J3, ICOSLG, SOD1 | NR3C2 4372/4885SMN1; SMN2 1859/4885PTPN11 2155/4885 |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | NR3C2 167/4885SMN1; SMN2 2000/4885PTPN11 749/4885 |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | NR3C2 247/4885SMN1; SMN2 267/4885PTPN11 853/4885 |
| US-11279713-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | NR3C2 167/4885SMN1; SMN2 2000/4885PTPN11 749/4885 |
| US-20220069238-A1 | IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING THE COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THE COMPOUND, DISPLAY DEVICE, AND ILLUMINATION DEVICE | INF2, EMC2, INTS9 | NR3C2 619/4885SMN1; SMN2 2768/4885PTPN11 2215/4885 |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | EPOR, CBR1, CBR3 | NR3C2 260/4885SMN1; SMN2 2425/4885PTPN11 554/4885 |
| US-20120077799-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | NR3C2 167/4885SMN1; SMN2 2000/4885PTPN11 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.